{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alprazolam+2+MG",
    "query": {
      "intervention": "Alprazolam 2 MG"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alprazolam+2+MG&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T10:45:27.384Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04970342",
      "title": "Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Driving Behavior",
        "Driving Under the Influence"
      ],
      "interventions": [
        {
          "name": "Placebo (Lactose) Capsule",
          "type": "DRUG"
        },
        {
          "name": "0.75 mg Alprazolam Capsule",
          "type": "DRUG"
        },
        {
          "name": "Cannabis (6.18% THC / <0.025% CBD)",
          "type": "DRUG"
        },
        {
          "name": "Cannabis (0%/ THC / 0% CBD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Timothy L. Brown",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "19 Years to 45 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-07-16",
      "completion_date": "2021-08-21",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04970342"
    },
    {
      "nct_id": "NCT00635076",
      "title": "A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Panic Disorder"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "alprazolam XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 3,
      "start_date": "2004-07",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 3,
      "location_summary": "Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Middleton",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635076"
    },
    {
      "nct_id": "NCT03398083",
      "title": "Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cannabis Use Disorder"
      ],
      "interventions": [
        {
          "name": "THC",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        },
        {
          "name": "CBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2017-12-04",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398083"
    },
    {
      "nct_id": "NCT00592332",
      "title": "Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "control group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 56,
      "start_date": "2005-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00592332"
    },
    {
      "nct_id": "NCT00703885",
      "title": "PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "0.25 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-01",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2014-12-22",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703885"
    },
    {
      "nct_id": "NCT00356278",
      "title": "D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stress Disorder, Post Traumatic"
      ],
      "interventions": [
        {
          "name": "D-Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Virtual Reality Exposure Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 156,
      "start_date": "2006-09",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-01-08",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00356278"
    },
    {
      "nct_id": "NCT01188057",
      "title": "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG",
          "type": "DRUG"
        },
        {
          "name": "NIRAVAM TM 2 mg orally disintegrating tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-25",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188057"
    },
    {
      "nct_id": "NCT03286218",
      "title": "A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recreational Drug Use",
        "Prescription Drug Abuse (Not Dependent)"
      ],
      "interventions": [
        {
          "name": "Lasmiditan",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2017-09-15",
      "completion_date": "2017-11-20",
      "has_results": true,
      "last_update_posted_date": "2020-01-10",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286218"
    },
    {
      "nct_id": "NCT00477451",
      "title": "Staccato Alprazolam in Panic Attack",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment of Induced Panic Attack"
      ],
      "interventions": [
        {
          "name": "Inhaled placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled alprazolam 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "IV doxapram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 49,
      "start_date": "2007-05",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 3,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477451"
    },
    {
      "nct_id": "NCT00662259",
      "title": "Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Alprazolam (Xanax)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2008-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-25",
      "last_synced_at": "2026-09-15T10:45:27.384Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662259"
    }
  ]
}